Open access
Open access
Powered by Google Translator Translator

Lipids

#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.

30 Aug, 2022 | 12:16h | UTC

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials – The Lancet

News Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology

Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD

 


Consensus Statement | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis.

30 Aug, 2022 | 12:10h | UTC

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement – European Heart Journal

 

Commentary on Twitter

 


#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.

30 Aug, 2022 | 12:12h | UTC

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease – Circulation

News Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology

Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine

 

Commentary on Twitter

 


USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.

24 Aug, 2022 | 14:21h | UTC

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement – JAMA

Editorials:

Statins for Primary Cardiovascular Disease Prevention: Time to Curb Our Enthusiasm – JAMA Internal Medicine

Statins and Primary Atherosclerotic Cardiovascular Disease Prevention—What We Know, Where We Need to Go, and Why Are We Not There Already? – JAMA Network Open

Evidence Report: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Author Interview: USPSTF Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults – JAMA

Patient Page: Statins for the Prevention of Cardiovascular Disease – JAMA

Commentary: Latest statins guidance keeps more conservative approach to preventing first stroke or heart attack – CNN

 


Position Paper | Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients.

16 Aug, 2022 | 13:42h | UTC

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP) – Journal of Sarcopenia, Cachexia and Muscle

 


Clinical Practice Update | The detection, evaluation, and management of dyslipidemia in children and adolescents.

15 Aug, 2022 | 12:12h | UTC

The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update – Canadian Journal of Cardiology

 


Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function.

12 Aug, 2022 | 15:11h | UTC

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function – Journal of the American College of Cardiology

Commentaries:

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution – TCTMD

Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies – American College of Cardiology

 


In a cohort study with a median follow‐up of 23.2 years, both very low and very high LDL‐C levels are associated with increased risk of cardiovascular mortality in the general population.

4 Aug, 2022 | 14:25h | UTC

Association of Low‐Density Lipoprotein Cholesterol Levels with More than 20‐Year Risk of Cardiovascular and All‐Cause Mortality in the General Population – Journal of the American Heart Association

 


Position Paper | Red yeast rice for dyslipidemias and cardiovascular risk reduction.

29 Jul, 2022 | 12:35h | UTC

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A Position Paper of the International Lipid Expert Panel – Pharmacological Research

 


Consensus statement on the management of familial hypercholesterolemia.

28 Jul, 2022 | 13:16h | UTC

2022 Consensus statement on the management of familial hypercholesterolemia in Korea – The Korean Journal of Internal Medicine

 


Chasing LDL cholesterol to the bottom — PCSK9 in perspective.

22 Jul, 2022 | 11:36h | UTC

Chasing LDL cholesterol to the bottom — PCSK9 in perspective – Nature Cardiovascular Research (if the link is paywalled, try this one)

 

Commentary on Twitter

 


DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

21 Jul, 2022 | 13:11h | UTC

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases – Journal of Diabetes and its Complications

 


Open-label RCT | Moderate-intensity statin plus ezetimibe is noninferior to high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease.

20 Jul, 2022 | 12:32h | UTC

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

 


Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolemia.

18 Jul, 2022 | 11:18h | UTC

Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician – Journal of Paediatrics and Child Health

 


Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988).

18 Jul, 2022 | 11:09h | UTC

Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988) – Archives of Medical Sciences

 


NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.

12 Jul, 2022 | 12:48h | UTC

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient – Journal of Clinical Lipidology

Commentary: National Lipid Association Scientific Statement on Statin Intolerance – American College of Cardiology

 


Key studies published in 2021 related to primary prevention of atherosclerotic cardiovascular disease.

5 Jul, 2022 | 12:12h | UTC

Highlights in ASCVD Primary Prevention for 2021 – Journal of the American Heart Association


Stay Updated in Your Specialty

No spam, just news.